Modern Interventional Treatments for Meibomian Gland Dysfunc

Name: Modern Interventional Treatments for Meibomian Gland Dysfunction
Uploaded: 2023-03-10T05:00:00+00:00
Duration: 16 min
Description: In this video, Douglas K. Devries, OD, and Hardeep Kataria, OD, FAAO, discuss some findings from the Interventional Meibomian Gland Dysfunction (MGD) Conse

Media formats available:

Details

Presenters

Overview
In this video, Douglas K. Devries, OD, and Hardeep Kataria, OD, FAAO, discuss some findings from the Interventional Meibomian Gland Dysfunction (MGD) Consensus, namely those related to the use of modern interventional MGD treatments. Moreover, Drs. Devries and Kataria review various palliative and prescription MGD treatment options and discuss how interventional MGD treatments differ from more conventional treatments. The faculty also discuss the importance of patient education when incorporating interventional MGD treatments into a standard clinical practice.
This independent educational activity is supported by unrestricted educational grants from Alcon, Johnson & Johnson Vision, and Sight Sciences.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Understand the different types of mechanical MGD treatments and how these differ from other types of MGD treatments
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Faculty and Disclosures
Douglas K. Devries, OD
Co-Founder and Managing Partner
Eye Care Associates of Nevada
Sparks, NV

Hardeep Kataria, OD, FAAO
Avant Eyes Optometry
Porter Ranch, CA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Douglas K. Devries, OD, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Akorn, Alcon, Avellino, Azura, BlephEx, Bruder, Novartis, Quidel, Tarsus, TearLab, Theá, and Visus. Advisory Board/Speaker’s Bureau: Allergan, Bausch + Lomb, BioTissue, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, OcuSoft, ScienceBased Health, Sight Sciences, and Sun Pharmaceutical Industries. Partner: Ophthalmic Resources. Share/Stockholder: RPS. Speaker’s Bureau: Lumenis.
Hardeep Kataria, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: BioTissue and Tarsus.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Alcon, Johnson & Johnson Vision, or Sight Sciences.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 03/10/2023

Douglas K. Devries, OD

Guest

Hardeep Kataria, OD, FAAO

Guest

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

The Missed Diagnosis: A 45-Year-Old Software Engineer Who Complains of Dry Eyes
The Missed Diagnosis: A 45-Year-Old Software Engineer Who Complains of Dry Eyes
MinuteCE®
The Missed Diagnosis: A 45-Year-Old Software Engineer Who Complains of Dry Eyes
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit
At the Intersection of DB, DED, MGD, and Other Forms of Blepharitis
At the Intersection of DB, DED, MGD, and Other Forms of Blepharitis
MinuteCE®
At the Intersection of DB, DED, MGD, and Other Forms of Blepharitis
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit
Key Takeaways and Practice Integration
Key Takeaways and Practice Integration
MinuteCE®
Key Takeaways and Practice Integration
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
MinuteCE®
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit

Modern Interventional Treatments for Meibomian Gland Dysfunction

Overview

Learning Objectives

Participation Method

Faculty and Disclosures

Disclaimer

System Requirements

Publication Dates

Recommended

Title